Steve Freed: Please tell us a little about yourself and this new compound, BTI320. Dr. David Platt: My area of expertise is the recognition between carbohydrate and protein. In my previous two companies, I developed drugs for a recognition between sugar and protein. In one case, it was a protein that …

Steve Freed: Let’s start out with a little background about Qsymia and Belviq. What is the FDA allowing you to treat with the drugs? Dr. Timothy Garvey: In 2012, the FDA approved two new weight loss medications. In 2014, another medication was approved. That is three new medications. We hope …

Steve Freed, Publisher, Diabetes in Control: When do you think you might be able to submit to the FDA? Joe Cook, Jr: Having developed a number of medicines, they all have their own character. It’s like children. They all come with different presentations. If the data from this study are very clear …

This week, we continue our exclusive short interview series with NuSirt CEO, JC, in which he talks about some of the groundbreaking work his company is doing to increase the effectiveness of metformin.   Steve Freed, Publisher, Diabetes in Control: What actually brought you to taking this compound and combining it …

This week, we’re taking a break from our regularly featured section on avoiding medication mistakes to bring you this exclusive interview series with NuSirt CEO, JC, in which he talks about some of the groundbreaking work his company is doing to increase the effectiveness of metformin. Steve Freed, Publisher, Diabetes …

This week, we are taking a break from our Clinical Text presentations, to bring you this exclusive interview with Al Mann, the legendary founder of Mannkind Corp, and the person primarily responsible for backing the development of the inhaled insulin product, Afrezza, soon to be on the market. Steve Freed: …

The Future of Islet Transplantation Steve Freed: Please give tell us a little bit about yourself, and your field of interest. Dr. Eli Lewis: I studied in the medical school at Ben-Gurion University of the Negev (BGU) in Israel. During medical school, I was infatuated by medical research. I then completed …

Countless seniors rely on diabetic testing supplies (DTS) from their pharmacists in order to live with and manage their disease. Unfortunately, an expansion of Medicare’s Competitive Bidding Program could disrupt that relationship and make it harder for seniors to obtain their DTS. Many seniors choose to obtain their diabetes testing …

In a special bonus issue of our GLP-1 Special Series, we presented this excellent and informative interview with Dr. Alan Moses, Global CMO, Novo Nordisk. Dr. Moses gave us his take on the latest in GLP-1 technologies as well as a peek at Novo’s efforts in developing world-class therapies in …

Diabetes In Control Publisher Steve Freed interviewed Dr. David D’Alessio, Associate Professor of Medicine, Division of Endocrinology, University of Cincinnati, and the Albert Vontz chair in Diabetes Research. Dr. D’Alessio helps us understand some of the newest research on GLP-1’s, how he uses these therapies in his own practice and …